New SFDA Approval Brings Diagnostic Devices for Antipsychotic Blood Monitoring

The Kingdom of Saudi Arabia has been working nonstop towards providing better healthcare solutions, keeping their promise of enhancing the healthcare sector as part of the Saudi Vision 2030.

One of the steps that has been made towards bettering the healthcare system was the approval of in-vitro diagnostic medical devices that utilize biotechnology to accurately sense concentrations of antipsychotic medications in the blood.

These tools were developed after extensive evaluation involving a thorough review of technical and clinical documentation, along with clinical trial data, under the supervision of specialized experts to confirm the devices’ safety and effectiveness.

These devices play a key role in managing conditions such as schizophrenia, manic episodes, and bipolar depression. By allowing physicians to precisely measure drug levels, track patient adherence, and adjust dosages, when necessary, they help achieve the optimal balance between treatment effectiveness and minimized side effects.

Built on advanced nanotechnology, the devices use a nanoparticle agglutination assay, where nanoparticles bind to drug-specific antibodies. Their accumulation is then measured with a spectrophotometer, delivering accurate blood-level readings and enabling more precise, safer, and effective treatment decisions.

Learn more: SFDA Approves Marketing Authorization for Diagnostic Medical Devices to Measure Antipsychotic Drug Levels in Blood | The official website of the Saudi Food and Drug Authority